WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part II: IPR & Zytiga – Competition Matters – Here, CAPA looks at how the IPR proceeding for the prostate cancer medicine Zytiga accelerated patient access to generic […]

Continue Reading

WHAT YOU NEED TO KNOW BY THE NUMBERS – A new Morning Consult poll conducted for the Campaign for Sustainable Rx Pricing (CSRxP) – a member of CAPA – found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform the U.S. healthcare system to lower costs and put […]

Continue Reading

WHAT YOU NEED TO KNOW MUST READ: CAPA Warns Recent Federal Circuit Court Decision Could Erode Hatch-Waxman, Lead to Even Higher Drug Prices Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), recently authored an op-ed in Bloomberg Law around the Federal Circuit’s recent decision in GlaxoSmithKline LLCTeva Pharmaceuticals USA, Inc.: “The Federal Circuit’s decision in GlaxoSmithKline […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Files Amicus Brief Urging the Supreme Court to Preserve IPR to Lower Drug Prices. DID YOU KNOW – The U.S. Supreme Court is reviewing Arthrex Inc. v. Smith & Nephew Inc. to determine the constitutionality of the Patent Trial and Appeal Board (PTAB). In an amicus brief filed recently, CAPA outlined […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA: The USPTO must prioritize patent quality and restore the IPR system to its proper focus. UPDATE – As part of its ongoing campaign to safeguard the U.S. patent system and stop Big Pharma from gaming the system, CAPA filed comments this week with the United States Patent and Trademark Office (USPTO).  The […]

Continue Reading

WHAT YOU NEED TO KNOW BREAKING NEWS: CAPA releases guidance for next Administration and Congress encouraging Washington to address Big Pharma’s abuses of the patent system that keeps drug prices high for patients and the entire U.S. healthcare system.  Continued exploitations of the U.S. patent process results in deadweight losses that get saddled on the backs […]

Continue Reading

WHAT YOU NEED TO KNOW A must-read report was recently released – The 2020 Access and Savings Report by the Association for Accessible Medicines (AAM) – a member of CAPA – that highlights the critical benefits of increasing access to alternative prescription drugs which can drive affordability for not only American patients, but the healthcare system as […]

Continue Reading

WHAT YOU NEED TO KNOW In case you missed it, the Coalition Against Patent Abuse applauded a recent decision by the U.S. House of Representatives’ Committee on Oversight and Reform to subpoena AbbVie, the drug company that makes Humira, as part of its probe into pricing practices by the big drug companies.   “CAPA applauds today’s announcement by the […]

Continue Reading

WHAT YOU NEED TO KNOW In case you missed it, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around rising prescription drug prices and the need for reforms that can encourage competition and innovation to drive access and affordability.  In his op-ed, Lane highlights a national survey by the Campaign for […]

Continue Reading

WHAT YOU NEED TO KNOW This week, Axios reported that Humira, a medicine that is prescribed to millions of people around the world, “continues to generate more U.S. revenue than any other drug, due to AbbVie extending U.S. patents and consequently retaining higher U.S. prices.”   WHAT YOU NEED TO KNOW: While Humira is notably one of the […]

Continue Reading